Progress in surgical and systematic treatment of intrahepatic cholangiocarcinoma

doi:10.3877/cma.j.issn.2095-3232.2025033

Abstract

Abstract:

Intrahepatic cholangiocarcinoma （ICC） is one of primary malignant tumors of the liver，and its incidence rate has been elevated year by year in China.Surgical resection is the major treatment for ICC patients to obtain long-term survival.In recent years， systematic therapy， especially immunotherapy， has developed rapidly and exerted significant impact on surgical treatment.In this article， the latest progress in surgical treatment of ICC was reviewed， focusing on surgery-based systematic treatment， such as adjuvant therapy and neoadjuvant therapy， etc.

Key words: Intrahepatic cholangiocarcinoma, Hepatectomy, Conversion therapy, Systemic therapy

Zhiwen Ding, Yiming Zhao, Lu Wang. Progress in surgical and systematic treatment of intrahepatic cholangiocarcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 187-196.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2025033

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2025/V14/I02/187

References 76

［1］	Zhang H， Yang T， Wu M， et al.Intrahepatic cholangiocarcinoma：Epidemiology， risk factors， diagnosis and surgical management［J］.C a n c e r L e t t， 2 0 1 6， 3 7 9（2）： 1 9 8-2 0 5.D O I： 1 0.1 0 1 6/j.canlet.2015.09.008.
［2］	Valle JW， Kelley RK， Nervi B， et al.Biliary tract cancer［J］.Lancet，2021， 397（10272）： 428-444.DOI： 10.1016/s0140-6736（21）00153-7.
［3］	Izquierdo-Sanchez L， Lamarca A， La Casta A， et al.Cholangiocarcinoma landscape in Europe： diagnostic， prognostic and therapeutic insights from the ENSCCA Registry［J］.J Hepatol， 2022， 76（5）： 1109-1121.DOI： 10.1016/j.jhep.2021.12.010.
［4］	Chaiteerakij R， Harmsen WS， Marrero CR， et al.A new clinically based staging system for perihilar cholangiocarcinoma［J］.Am J Gastroenterol， 2014， 109（12）： 1881-1890.DOI： 10.1038/ajg.2014.327.
［5］	Glantzounis GK， Tokidis E， Basourakos SP， et al.The role of portal vein embolization in the surgical management of primary hepatobiliary cancers：a systematic review［J］.Eur J Surg Oncol， 2017， 43（1）： 32-41.DOI： 10.1016/j.ejso.2016.05.026.
［6］	Amin MBES， Greene F， Byrd DR， et al.AJCC cancer staging manual ［M］.8th ed.New York： Springer， 2017.
［7］	Kubo S， Shinkawa H， Asaoka Y， et al.Liver cancer study group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma［J］.Liver Cancer， 2022， 11（4）： 290-314.DOI： 10.1159/000522403.
［8］	Okabayashi T， Yamamoto J， Kosuge T， et al.A new staging system for mass-forming intrahepatic cholangiocarcinoma： analysis of preoperative and postoperative variables［J］.Cancer， 2001， 92（9）：2374-2383.DOI： 10.1002/1097-0142（20011101）92： 9＜2374： aidcncr1585＞3.0.co；2-l.
［9］	Spolverato G， Bagante F， Weiss M， et al.Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma［J］.J Surg Oncol， 2017， 115（6）： 696-703.DOI： 10.1002/jso.24569.
［10］	Cheng Z， Lei Z， Si A， et al.Modifications of the AJCC 8th edition staging system for intrahepatic cholangiocarcinoma and proposal for a new staging system by incorporating serum tumor markers［J］.HPB，2019， 21（12）： 1656-1666.DOI： 10.1016/j.hpb.2019.05.010.
［11］	Lamarca A， Santos-Laso A， Utpatel K， et al.Liver metastases of intrahepatic cholangiocarcinoma： implications for an updated staging system［J］.Hepatology， 2021， 73（6）： 2311-2325.DOI： 10.1002/hep.31598.
［12］	Farges O， Fuks D， Boleslawski E， et al.Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma：a multicenter study by the AFC-IHCC-2009 study group［J］.Ann Surg， 2011， 254（5）： 824-829；discussion830.DOI： 10.1097/SLA.0b013e318236c21d.
［13］	Esnaola NF， Meyer JE， Karachristos A， et al.Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma［J］.Cancer， 2016， 122（9）： 1349-1369.DOI： 10.1002/cncr.29692.
［14］	Amini N， Ejaz A， Spolverato G， et al.Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States： a population-based analysis［J］.J Surg Oncol， 2014， 110（2）：163-170.DOI： 10.1002/jso.23605.
［15］	European Association for the Study of the Liver.EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma［J］.J Hepatol， 2023， 79（1）： 181-208.DOI：10.1016/j.jhep.2023.03.010.
［16］	Lamarca A， Barriuso J， Chander A， et al.¹⁸F-fluorodeoxyglucose positron emission tomography （¹⁸FDG-PET） for patients with biliary tract cancer： systematic review and meta-analysis［J］.J Hepatol， 2019，71（1）： 115-129.DOI： 10.1016/j.jhep.2019.01.038.
［17］	Moris D， Palta M， Kim C， et al.Advances in the treatment of intrahepatic cholangiocarcinoma： an overview of the current and future therapeutic landscape for clinicians［J］.CA Cancer J Clin， 2023，73（2）： 198-222.DOI： 10.3322/caac.21759.
［18］	Mazzaferro V， Gorgen A， Roayaie S， et al.Liver resection and transplantation for intrahepatic cholangiocarcinoma［J］.J Hepatol，2020， 72（2）： 364-377.DOI： 10.1016/j.jhep.2019.11.020.
［19］	Utada M， Ohno Y， Tamaki T， et al.Long-term trends in incidence and mortality of intrahepatic and extrahepatic bile duct cancer in Japan［J］.J Epidemiol， 2014， 24（3）： 193-199.DOI： 10.2188/jea.je20130122.
［20］	Yamamoto M， Ariizumi SI.Surgical outcomes of intrahepatic cholangiocarcinoma［J］.Surg Today， 2011， 41（7）： 896-902.DOI：10.1007/s00595-011-4517-z.
［21］	Si A， Li J， Yang Z， et al.Impact of anatomical versus non-anatomical liver resection on short- and long-term outcomes for patients with intrahepatic cholangiocarcinoma［J］.Ann Surg Oncol， 2019， 26（6）：1841-1850.DOI： 10.1245/s10434-019-07260-8.
［22］	Endo I， Gonen M， Yopp AC， et al.Intrahepatic cholangiocarcinoma：rising frequency， improved survival， and determinants of outcome after resection［J］.Ann Surg， 2008， 248（1）： 84-96.DOI： 10.1097/SLA.0b013e318176c4d3.
［23］	Sotiropoulos GC， Bockhorn M， Sgourakis G， et al.R0 liver resections for primary malignant liver tumors in the noncirrhotic liver： a diagnosis-related analysis［J］.Dig Dis Sci， 2009， 54（4）： 887-894.DOI：10.1007/s10620-008-0408-6.
［24］	Tomimaru Y， Eguchi H， Wada H， et al.Surgical outcomes of liver resection combined with inferior vena cava resection and reconstruction with artificial vascular graft［J］.Dig Surg， 2019， 36（6）：502-508.DOI： 10.1159/000493434.
［25］	Reames BN， Ejaz A， Koerkamp BG， et al.Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma： a multi-institutional analysis［J］.J Surg Oncol，2017， 116（2）： 133-139.DOI： 10.1002/jso.24633.
［26］	Zhang XF， Bagante F， Chakedis J， et al.Perioperative and long-term outcome for intrahepatic cholangiocarcinoma： impact of major versus minor hepatectomy［J］.J Gastrointest Surg， 2017， 21（11）： 1841-1850.DOI： 10.1007/s11605-017-3499-6.
［27］	Paul Wright G， Perkins S， Jones H， et al.Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma： a comparison of surgical resection with intra-arterial therapies［J］.Ann Surg Oncol， 2018， 25（1）： 83-90.DOI： 10.1245/s10434-017-6110-1.
［28］	Franssen S， Soares KC， Jolissaint JS， et al.Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with multifocal intrahepatic cholangiocarcinoma［J］.JAMA Surg， 2022，157（7）： 590-596.DOI： 10.1001/jamasurg.2022.1298.
［29］	Yin L， Zhao S， Zhu H， et al.Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study［J］.Sci Rep， 2021， 11（1）： 12166.DOI：10.1038/s41598-021-91823-x.
［30］	Buettner S， Ten Cate DWG， Bagante F， et al.Survival after resection of multiple tumor foci of intrahepatic cholangiocarcinoma［J］.J Gastrointest Surg， 2019， 23（11）： 2239-2246.DOI： 10.1007/s11605-019-04184-2.
［31］	Li J， Moustafa M， Linecker M， et al.ALPPS for locally advanced intrahepatic cholangiocarcinoma： did aggressive surgery lead to the oncological benefit？ an international multi-center study［J］.Ann Surg Oncol， 2020， 27（5）： 1372-1384.DOI： 10.1245/s10434-019-08192-z.
［32］	Fong ZV， Brownlee SA， Qadan M， et al.The clinical management of cholangiocarcinoma in the United States and Europe： a comprehensive and evidence-based comparison of guidelines［J］.Ann Surg Oncol，2021， 28（5）： 2660-2674.DOI： 10.1245/s10434-021-09671-y.
［33］	Benson AB， D’Angelica MI， Abbott DE， et al.Hepatobiliary cancers，version 2.2021， NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw， 2021， 19（5）： 541-565.DOI： 10.6004/jnccn.2021.0022.
［34］	Group CW.Italian clinical practice guidelines on cholangiocarcinomapart Ⅱ： treatment［J］.Dig Liver Dis， 2020， 52（12）： 1430-1442.DOI： 10.1016/j.dld.2020.08.030.
［35］	中国抗癌协会肝癌专业委员会胆管癌协作组.原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识（2022版）［J］.中华消化外科杂志， 2022， 21（10）： 1269-1301.DOI： 10.3760/cma.j.cn115610-20220829-00476.Chinese Society of Liver Cancer Cholangiocarcinoma Cooperative Group.Chinese expert consensus on management of intrahepatic cholangiocarcinoma （2022 edition）［J］.Chin J Dig Surg， 2022， 21（10）：1269-1301.DOI： 10.3760/cma.j.cn115610-20220829-00476.
［36］	Sposito C， Ratti F， Cucchetti A， et al.Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma［J］.J Hepatol， 2023，78（2）： 356-363.DOI： 10.1016/j.jhep.2022.10.021.
［37］	Rahim MK， Okholm TLH， Jones KB， et al.Dynamic CD8⁺ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes［J］.Cell， 2023， 186（6）： 1127-1143.e18.DOI： 10.1016/j.cell.2023.02.021.
［38］	Sahara K， Tsilimigras DI， Merath K， et al.Therapeutic index associated with lymphadenectomy among patients with intrahepatic cholangiocarcinoma： which patients benefit the most from nodal evaluation？［J］.Ann Surg Oncol， 2019， 26（9）： 2959-2968.DOI：10.1245/s10434-019-07483-9.
［39］	Zhou R， Lu D， Li W， et al.Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma？ A systematic review and meta-analysis［J］.HPB， 2019， 21（7）： 784-792.DOI： 10.1016/j.hpb.2018.12.011.
［40］	Zhang XF， Xue F， Dong DH， et al.Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis［J］.Ann Surg， 2021， 274（6）：e1187-e1195.DOI： 10.1097/SLA.0000000000003788.
［41］	Kim SH， Han DH， Choi GH， et al.Extent of lymph node dissection for accurate staging in intrahepatic cholangiocarcinoma［J］.J Gastrointest Surg， 2022， 26（1）： 70-76.DOI： 10.1007/s11605-021-05039-5.
［42］	Ratti F， Cipriani F， Ariotti R， et al.Safety and feasibility of laparoscopic liver resection with associated lymphadenectomy for intrahepatic cholangiocarcinoma： a propensity score-based casematched analysis from a single institution［J］.Surg Endosc， 2016，30（5）： 1999-2010.DOI： 10.1007/s00464-015-4430-4.
［43］	Lee W， Park JH， Kim JY， et al.Comparison of perioperative and oncologic outcomes between open and laparoscopic liver resection for intrahepatic cholangiocarcinoma［J］.Surg Endosc， 2016， 30（11）： 4835-4840.DOI： 10.1007/s00464-016-4817-x.
［44］	Kinoshita M， Kanazawa A， Takemura S， et al.Indications for laparoscopic liver resection of mass-forming intrahepatic cholangiocarcinoma［J］.Asian J Endosc Surg， 2020， 13（1）： 46-58.DOI： 10.1111/ases.12703.
［45］	Meyer CG， Penn I， James L.Liver transplantation for cholangiocarcinoma： results in 207 patients［J］.Transplantation， 2000， 69（8）：1633-1637.DOI： 10.1097/00007890-200004270-00019.
［46］	Sapisochin G， Facciuto M， Rubbia-Brandt L， et al.Liver transplantation for “very early” intrahepatic cholangiocarcinoma：International retrospective study supporting a prospective assessment［J］.Hepatology， 2016， 64（4）： 1178-1188.DOI： 10.1002/hep.28744.
［47］	De Martin E， Rayar M， Golse N， et al.Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis［J］.Liver Transpl， 2020， 26（6）： 785-798.DOI： 10.1002/lt.25737.
［48］	Lunsford KE， Javle M， Heyne K， et al.Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy： a prospective case-series［J］.Lancet Gastroenterol Hepatol，2018， 3（5）： 337-348.DOI： 10.1016/S2468-1253（18）30045-1.
［49］	Valle J， Wasan H， Palmer DH， et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer［J］.N Engl J Med， 2010， 362（14）：1273-1281.DOI： 10.1056/NEJMoa0908721.
［50］	Lee J， Park SH， Chang HM， et al.Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer： a multicentre， openlabel， randomised， phase 3 study［J］.Lancet Oncol， 2012， 13（2）： 181-188.DOI： 10.1016/S1470-2045（11）70301-1.
［51］	Rimini M， Fornaro L， Lonardi S， et al.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer： an early exploratory analysis of real-world data［J］.Liver Int， 2023， 43（8）： 1803-1812.DOI：10.1111/liv.15641.
［52］	Oh DY， He AR， Qin S， et al.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer［J］.NEJM Evid， 2022， 1（8）：EVIDoa2200015.DOI： 10.1056/EVIDoa2200015.
［53］	Kim ST， Kang JH， Lee J， et al.Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers： a multicenter， open-label， randomized， phase III， noninferiority trial［J］.Ann Oncol， 2019， 30（5）： 788-795.DOI：10.1093/annonc/mdz058.
［54］	Morizane C， Okusaka T， Mizusawa J， et al.Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer： the FUGA-BT （JCOG1113） randomized phase Ⅲclinical trial［J］.Ann Oncol， 2019， 30（12）： 1950-1958.DOI： 10.1093/annonc/mdz402.
［55］	Ioka T， Kanai M， Kobayashi S， et al.Randomized phase III study of gemcitabine， cisplatin plus S-1 versus gemcitabine， cisplatin for advanced biliary tract cancer （KHBO1401- MITSUBA）［J］.J Hepatobiliary Pancreat Sci， 2023， 30（1）： 102-110.DOI： 10.1002/jhbp.1219.
［56］	Le Roy B， Gelli M， Pittau G， et al.Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma［J］.Br J Surg，2018， 105（7）： 839-847.DOI： 10.1002/bjs.10641.
［57］	Martin RCG 2nd， Simo KA， Hansen P， et al.Drug-eluting bead，irinotecan therapy of unresectable intrahepatic cholangiocarcinoma（DELTIC） with concomitant systemic gemcitabine and cisplatin［J］.Ann Surg Oncol， 2022， 29（9）： 5462-5473.DOI： 10.1245/s10434-022-11932-3.
［58］	Cercek A， Boerner T， Tan BR， et al.Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma： a phase 2 clinical trial［J］.JAMA Oncol， 2020，6（1）： 60-67.DOI： 10.1001/jamaoncol.2019.3718.
［59］	Geschwind JFH， Salem R， Carr BI， et al.Yttrium-90 microspheres for the treatment of hepatocellular carcinoma［J］.Gastroenterology， 2004，127（5 Suppl 1）： S194-S205.DOI： 10.1053/j.gastro.2004.09.034.
［60］	Ibrahim SM， Mulcahy MF， Lewandowski RJ， et al.Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres：results from a pilot study［J］.Cancer， 2008， 113（8）： 2119-2128.DOI：10.1002/cncr.23818.
［61］	Edeline J， Touchefeu Y， Guiu B， et al.Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma： a phase 2 clinical trial［J］.JAMA Oncol， 2020，6（1）： 51-59.DOI： 10.1001/jamaoncol.2019.3702.
［62］	Sutton TL， Billingsley KG， Walker BS， et al.Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma［J］.Am J Surg， 2021， 221（6）： 1182-1187.DOI： 10.1016/j.amjsurg.2021.02.029.
［63］	Yadav S， Xie H， Bin-Riaz I， et al.Neoadjuvant vs.adjuvant chemotherapy for cholangiocarcinoma： a propensity score matched analysis［J］.Eur J Surg Oncol， 2019， 45（8）： 1432-1438.DOI： 10.1016/j.ejso.2019.03.023.
［64］	Mason MC， Massarweh NN， Tzeng CD， et al.Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma？ implications from the neoadjuvant experience［J］.Ann Surg Oncol， 2021， 28（11）：6725-6735.DOI： 10.1245/s10434-020-09536-w.
［65］	Maithel SK， Keilson JM， Cao HST， et al.NEO-GAP： a single-arm，phaseⅡfeasibility trial of neoadjuvant gemcitabine， cisplatin， and nabpaclitaxel for resectable， high-risk intrahepatic cholangiocarcinoma［J］.Ann Surg Oncol， 2023， 30（11）： 6569-6570.DOI： 10.1245/s10434-023-13874-w.
［66］	Tsilimigras DI， Sahara K， Wu L， et al.Very early recurrence after liver resection for intrahepatic cholangiocarcinoma： considering alternative treatment approaches［J］.JAMA Surg， 2020， 155（9）： 823-831.DOI：10.1001/jamasurg.2020.1973.
［67］	Primrose JN， Fox RP， Palmer DH， et al.Capecitabine compared with observation in resected biliary tract cancer （BILCAP）： a randomised，controlled， multicentre， phase 3 study［J］.Lancet Oncol， 2019， 20（5）：663-673.DOI： 10.1016/S1470-2045（18）30915-X.
［68］	Bridgewater J， Fletcher P， Palmer DH， et al.Long-term outcomes and exploratory analyses of the randomized phase Ⅲ BILCAP study［J］.J Clin Oncol， 2022， 40（18）： 2048-2057.DOI： 10.1200/JCO.21.02568.
［69］	Nakachi K， Ikeda M， Konishi M， et al.Adjuvant S-1 compared with observation in resected biliary tract cancer （JCOG1202，ASCOT）： a multicentre， open-label， randomised， controlled， phase 3 trial［J］.Lancet， 2023， 401（10372）： 195-203.DOI： 10.1016/S0140-6736（22）02038-4.
［70］	Edeline J， Benabdelghani M， Bertaut A， et al.Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer （PRODIGE 12-ACCORD 18-UNICANCER GI）： a randomized phase Ⅲ study［J］.J Clin Oncol， 2019， 37（8）： 658-667.DOI： 10.1200/JCO.18.00050.
［71］	胡笛，黄金涛，仲斌演，等.肝内胆管癌的诊疗进展［J］.临床肝胆病杂志，2024，40（7）：1470-1476.DOI：10.12449/JCH240728.Hu D， Huang JT， Zhong BY，et al.Advances in the diagnosis and treatment of intrahepatic cholangiocarcinoma［J］.J Clin Hepatol，2024，40（7）：1470-1476.DOI：10.12449/JCH240728.
［72］	Oh DY， Lee KH， Lee DW， et al.Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer： an open-label， singlecentre， phase 2 study［J］.Lancet Gastroenterol Hepatol， 2022， 7（6）：522-532.DOI： 10.1016/S2468-1253（22）00043-7.
［73］	Abou-Alfa GK， Macarulla T， Javle MM， et al.Ivosidenib in IDH1-mutant， chemotherapy-refractory cholangiocarcinoma （ClarIDHy）： a multicentre， randomised， double-blind， placebo-controlled， phase 3 study［J］.Lancet Oncol， 2020， 21（6）： 796-807.DOI： 10.1016/S1470-2045（20）30157-1.
［74］	Javle M， Roychowdhury S， Kelley RK， et al.Infigratinib （BGJ398）in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements： mature results from a multicentre， open-label， single-arm， phase 2 study［J］.Lancet Gastroenterol Hepatol， 2021， 6（10）： 803-815.DOI： 10.1016/S2468-1253（21）00196-5.
［75］	Boilève A， Verlingue L， Hollebecque A， et al.Rare cancer， rare alteration： the case of NTRK fusions in biliary tract cancers［J］.Expert Opin Investig Drugs， 2021， 30（4）： 401-409.DOI： 10.1080/13543784.2021.1896703.
［76］	Zhu AX， Macarulla T， Javle MM， et al.Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation： the phase 3 randomized clinical ClarIDHy trial［J］.JAMA Oncol， 2021， 7（11）： 1669-1677.DOI： 10.1001/jamaoncol.2021.3836.

[1]	Yang Wei, Yuanquan Zhao, Xiaobo Wang, Hai Huang, Jie Chen. Risk analysis and prediction model establishment of early recurrence in patients with BCLC stage 0/A hepatocellular carcinoma after postoperative adjuvant therapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 157-161.
[2]	Yinzhen Pan, Xiuyu Zhang, Yantao Mai, Zhiqiang Liang. Clinical efficacy of two types of operation for intrahepatic cholangiocarcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 208-211.
[3]	Huazhi Li, Guang Cao, Diangang Liu, Yajing Zhang. Clinical comparison of descending hepatectomy with different approaches for primary hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 52-55.
[4]	Wang Feng, Zhenzhong Ma, Linhua Tang. Clinical study of CT scanning 3D reconstruction in laparoscopic hepatectomy for intrahepatic cholangiocarcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 104-107.
[5]	and Pancreatic Disease Prevention and Control Specialty Society of Chinese Prevention Medicine Association Hepatobiliary, Branch of China International Exchange and Promotive Association for Medical and Healthcare Hepato-Oncology. Chinese expert consensus on precision guidance technology in diagnosis and treatment of liver tumors（2024 edition） [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 145-157.
[6]	Zhejing Wu, Jingdong Li, Yongfu Xiong, Gang Liu, Lei Chen. Application of indocyanine green in anatomical hepatectomy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 25-29.
[7]	. Clinical status of laparoscopic living donor liver resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 30-35.
[8]	Zihui Ma, Weixing Guo. Clinical application of laparoscopic caudate lobe resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 36-40.
[9]	Zhongjing Huang, Lidong Zhang, Ziyi Wu, Junhua Ai. Transformational therapy for unresectable hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 41-45.
[10]	Chengshu Yu, Hongzhi Liu, Kecan Lin, Qizhu Lin, Tingfeng Huang, Weiping Zhou, Zhangjun Cheng, Jianying Lou, Shuguo Zheng, Xinyu Bi, Jianming Wang, Wei Guo, Fuyu Li, Jian Wang, Yamin Zheng, Jingdong Li, Shi Cheng, Yongyi Zeng. Risk factors of very early recurrence of intrahepatic cholangiocarcinoma after surgery [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 53-59.
[11]	Jiajun Li, Sile Wan, Chaoyang Lu. Clinical analysis of bile leakage after surgical resection of central hepatic tumors [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 87-91.
[12]	Zhipeng Sun, Bin Shu, Liang Wang, Xin Huang, Pengfei Wang, Guangxin Li, Xiaojuan Wang, Gong Li, Shizhong Yang. Safety and efficacy of radiotherapy combined with targeted neoadjuvant immunotherapy for intrahepatic cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 92-96.
[13]	Weinan Li, Gang Yang, Yongfu Xiong, Qiang Li, Jingdong Li. Preliminary experience of ALPPS after TACE combined with targeted immunotherapy for middle stage and advanced liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 97-101.
[14]	Yi Yu, Aowen Xie, Jun Liu, Pan Wang, Dejian He, Xinran Peng, Zhangyong He, Yucheng He, Qiong Li, Hongtao Li, Guoyan Wang, Jian Zhou, Shenghui Liu, Yongjun Wang, Chunbo Zhao, Qingyao Duan. Application of full-process management with finger-pinching hepatectomy as the core technology in severe liver trauma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 107-112.
[15]	Bingcheng Meng, Hai Zhu, Hongbing Ren, Weimin Mao, Deling Wei, Banghao Xu, Jilong Wang, Zongrui Jin, Zhujing Lan, Keyu Huang, Tingting Lu, Ling Zhang, Ya Guo, Zhang Wen. Role of IGF-1-mediated FOXO signaling pathway in liver regeneration after ALPPS in rat models [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 118-125.

Please choose a citation manager

Content to export